StockGuru Shines its Spotlight on BioPharm Asia, Inc. (OTCBB: BFAR) As It Announces Preliminary Unaudited Third Quarter 2011 Results — December 6, 2011

StockGuru Shines its Spotlight on BioPharm Asia, Inc. (OTCBB: BFAR)  As It Announces Preliminary Unaudited Third Quarter 2011 Results  — December 6, 2011

Revenue Increases 5.6% to $47.2 Million; Net Income Up 6% to $6.9 Million

Dallas, Texas (December 6, 2011) – StockGuru Shines its Spotlight on BioPharm Asia, Inc. (OTCBB: BFAR), a producer, distributor and retailer of medical products in China, today announced its financial results for the three months and nine months ended September 30, 2011.  The Company closed up 172 percent on December 5, 2011, at 15 percent, trading in a fifty-two week range of $3.38 – 0.0336.

Third Quarter 2011 Financial Highlights

  • Revenue in the third quarter of 2011 rose to $47.2 million, an increase of $2.5 million, or 5.6%, over last year’s comparable period revenue of $44.7 million.
  • Gross profit in the third quarter was $14.6 million, an increase of $1.7 million or 13%, as compared to the $12.9 million for the same period in 2010.
  • Net income increased to $6.9 million, compared to $6.5 million in the third quarter of 2010.
  • Fully diluted earnings per share for the quarter increased to $0.138 from $0.13 in the prior year period.

The Company’s revenue increased by $2.5 million during the third quarter of 2011 over the comparable 2010 period largely as the result of the $ 4.9 million increase in the Company’s Herbal Planting segment, and a revenue increase of $0.5 million from the Company’s Hospital Management segment.

The revenue for nine months ended September 30, 2011 was $115.3 million, reflecting an increase of $13.3 million, or 13% from the comparable 2010 period. This primarily resulted from the Company’s herbal planting segment, which realized a 643% revenue increase of $9 million, due to the increased profitability of Tonghua Tianbao Wood Frog Cultivation Limited Company. The overwhelming market demand of wood frog for its wide usage in vitamins and traditional Chinese medicines drove the profit margin over 70% higher than the year prior.

Gross profit for three months ended September 30, 2011 was $14.6 million, up 13% from $12.9 million in the third quarter of 2010. Gross margin as a percentage of revenue increased to 31% for the third quarter 2011 from 29% for the same period in 2010. The Gross margin is virtually steady, however the Retail segment’s revenue was decreased to $18.7 million, down 13% from $21.4 million in the third quarter of 2010. The retail segment’s reduced sales was attributable in part to PRC government-mandated price reductions for products included in the national essential drug list, compounded by product cost increases during the period caused in part by the national inflation rate of 6.1% in the third quarter. Gross profit for nine months ended September 30, 2011 was $38.6 million, up from the prior year’s level of $31.2 million. Gross margin was 33.5%, slightly higher than the prior year’s gross margin of 30.6%.

Operating expenses for the third quarter of 2011 totaled $4.2 million, slightly higher than the comparable 2010 period. For the nine months ended September 30, 2011, operating expenses were $13.4 million, a $3.1 million increase from last year’s nine month results. This increase resulted primarily from additional expenses related to the hospital management segment, reflecting the cost structure associated with health care management, higher professional insurance and rental costs.

The Company’s improved revenue and gross profit resulted in net income for the third quarter 2011 of $6.9 million, or $0.14 per share, up 6% from the $6.5 million, or $0.13 per share, in the same period in 2010. For the nine months ended September 30, 2011, net income increased 11% to $17.3 million, or $0.35 per share, from $15.6 million, or $0.31 per share, in the comparable 2010 period.

As of September 30, 2011, the Company’s cash and cash equivalents were $19.4 million as compared to $17.1 million as of December 31, 2010.

About BioPharm Asia, Inc.

BioPharm Asia, Inc. is engaged in the retail sale of medical products in China, complemented by vertically integrated supporting functions that include the cultivation of Chinese herbal medicines, pharmaceutical production and wholesale medicine distribution. For more information, please visit

Forward-looking statement: Except for certain historical information contained herein, the matters discussed in this news release contain forward-looking statements, including, but not limited to, statements relating to future expansion plans and growth in sales. These forward-looking statements involve a number of risks and uncertainties. Actual results may differ materially from those implied herein due to a number of factors, including, but not limited to, uncertainties in product demand, risks related to doing business in China, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors discussed in the company’s most recent annual report and other filings with the U. S. Securities and Exchange Commission.


To get free alerts on this and other similar stocks, please register here:

What is the StockGuru Spotlight?

Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.

StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.

To feature a company in The StockGuru Spotlight please contact the Publisher at If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage. When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present. Additionally SG also discloses any anticipated compensation in the future. Compensation is typically in cash. Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

John Pentony, Publisher,

Tel: +1 469 252 3031